ARGX

argenx (ARGX)

argenx SE

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ARGX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/09	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/05/09	14:00	GlobeNewswire Inc.	argenx Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:ARGX	argenx SE
2024/05/08	19:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/05/08	06:30	GlobeNewswire Inc.	argenx announces results of Annual General Meeting of Shareholders	NASDAQ:ARGX	argenx SE
2024/05/07	14:00	GlobeNewswire Inc.	argenx to Present at BofA Securities 2024 Health Care Conference	NASDAQ:ARGX	argenx SE
2024/05/02	14:00	GlobeNewswire Inc.	argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024	NASDAQ:ARGX	argenx SE
2024/04/16	14:00	GlobeNewswire Inc.	argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	NASDAQ:ARGX	argenx SE
2024/03/27	15:00	GlobeNewswire Inc.	argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	NASDAQ:ARGX	argenx SE
2024/03/27	05:00	GlobeNewswire Inc.	argenx Announces Annual General Meeting of Shareholders on May 7, 2024	NASDAQ:ARGX	argenx SE
2024/03/26	15:00	GlobeNewswire Inc.	argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	NASDAQ:ARGX	argenx SE
2024/03/08	20:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/03/08	06:01	GlobeNewswire Inc.	argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	NASDAQ:ARGX	argenx SE
2024/03/01	06:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/02/29	15:00	GlobeNewswire Inc.	argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update	NASDAQ:ARGX	argenx SE
2024/02/26	15:00	GlobeNewswire Inc.	argenx to Present at Upcoming Investor Conferences	NASDAQ:ARGX	argenx SE
2024/02/22	15:00	GlobeNewswire Inc.	argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024	NASDAQ:ARGX	argenx SE
2024/02/20	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/02/20	15:00	GlobeNewswire Inc.	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	NASDAQ:ARGX	argenx SE
2024/01/18	20:10	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/01/18	15:00	GlobeNewswire Inc.	argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis	NASDAQ:ARGX	argenx SE
2024/01/08	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2024/01/08	15:00	GlobeNewswire Inc.	argenx Highlights 2024 Strategic Priorities	NASDAQ:ARGX	argenx SE
2024/01/02	15:00	GlobeNewswire Inc.	argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ARGX	argenx SE
2023/12/21	02:37	Dow Jones News	Argenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data Talk	NASDAQ:ARGX	argenx SE
2023/12/20	20:00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2023/12/20	15:00	GlobeNewswire Inc.	argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	NASDAQ:ARGX	argenx SE
2023/11/29	01:16	Dow Jones News	Argenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data Talk	NASDAQ:ARGX	argenx SE
2023/11/28	21:03	Dow Jones News	Argenx Shares Down After Vyvgart Study Misses Primary Endpoint	NASDAQ:ARGX	argenx SE
2023/11/28	20:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ARGX	argenx SE
2023/11/28	15:00	GlobeNewswire Inc.	argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia	NASDAQ:ARGX	argenx SE